Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-03-22
2005-03-22
Winkler, Ulrike (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A, C536S023100, C536S024300, C536S024310
Reexamination Certificate
active
06870040
ABSTRACT:
The invention provides isolated nucleic acids molecules, designated BAL nucleic acid molecules, which are differentially expressed in non-Hodgkin's lymphoma. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing BAL nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a BAL gene has been introduced or disrupted. The invention still further provides isolated BAL proteins, fusion proteins, antigenic peptides and anti-BAL antibodies. Diagnostic methods using compositions of the invention are also provided.
REFERENCES:
Lazar et al. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology (1988) vol. 8, No. 3, pp. 1247-52.*
Burgess et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. Journal of Cell Biol.*
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science (1990) vol. 247, pp. 1306-1310.*
Aguiar, R.C.T. et al. “TEL-AML1 fusion in acute lymphoblastic leukaemia of adults”British Journal of Haematology95:673-677 (1996).
Aguiar, R.C.T. et al. “Molecular characterization of a tissue-specific protein tyrosine phosphatase (PTP) and putative tumor suppressor which is down-regulated in high risk diffuse large B-cell lymphomas (DLB-CLs)”Blood90(Suppl. 1):491a, abstract 2185 (1997).
Aguiar, R.C.T. et al. “The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster”Leukemia11:233-238 (1997).
Aguiar, R.C.T. et al. “PTPROt: An Alternatively Spliced and Developmentally Regulated B-Lymphoid Phosphatase That Promotes G0/G1 Arrest”Blood94(7):2403-2413 (Oct. 1, 1999).
Bretscher, M.S. et al. “EGF induces recycling membrane to form ruffles”Current Biology8:721-724 (1998).
Cabanillas, F. et al. “Frequent Nonrandom Chromosome Abnormalities in 27 Patients with Untreated Large Cell Lymphoma and Immunoblastic Lymphoma”Cancer Research48:5557-5564 (Oct. 1, 1988).
GenBank Accession No. AA151346 zl25b01.r1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:502921 5′, mRNA sequence.
GenBank Accession No. AA475710 vh16d11.r1 Soares_mammary_gland_NbMMG Mus musculus cDNA clone IMAGE:875637 5′, mRNA sequence.
GenBank Accession No. AI157103 ud16c02.r1 Soares_thymus_2NbMT Mus musculus cDNA clone IMAGE:1446050 5′, mRNA sequence.
GenBank Accession No.Q02874 Core histone macro-H2A.1 (Histone macroH2A1) (mH2A1) (H2A.y) (H2A/y).
Liang, P. et al. “Differential Display of Eurkaryotic Messenger RNA by Means of the Polymerase Chain Reaction”Science257:967-971 (Aug. 14, 1992).
Mitelman, F. et al. “A breakpoint map of recurrent chromosomal rearrangements in human neoplasia”Nature Genetics5:417-474 (Apr. 1997).
Monni, O. et al. “Gain of 3q and Deletion of IIq22 Are Frequent Aberrations in Mantle Cell Lymphoma”Genes, Chromosomes&Cancer21:298-307 (1998).
Pehrson, J.R. et al. “Evolutionary conservation of histone macroH2A subtypes and domains”Nucleic Acids Research26(12):2837-2842 (1998).
Schouten, H.C. et al. “Chromosomal Abnormalities in Untreated Patients With Non-Hodgkin's Lymphoma: Associations With Histology, Clinical Characteristics, and Treatment Outcome”Blood75(9):1841-1847 (May 1, 1990).
Shipp et al. “A Predictive Model for Aggressive Non-Hodgkin's Lymphoma”New England Journal of Medicine329(14):987-994 (1993).
Shipp, M. et al. “Non-Hodgkin's Lymphomas”Cancer: Principles and Practice of Oncology, 5thEdition. Devita, Vincent T. (ed.); J.B. Lippincott Company, Philadelphia, PA, USA: pp. 2165-2220 (1997).
Warrick, H.M. et al. “Myosin Structure and Function in Cell Motility”Ann. Rev. Cell Biol. 3:379-421 (1987).
Yakushijin, Y. et al. “A Directly Spliced Exon 10-Containing CD44 Variant Promotes the Metastasis and Homotypic Aggregation of Aggressive Non-Hodgkin's Lymphoma”Blood91(11):4282-4291 (Jun. 1, 1998).
Aguiar Ricardo
Shipp Margaret
Yakushijin Yoshi
Dana-Farber Cancer Institute
Lahive & Cockfield LLP
Smith, Esq. DeAnn F.
Winkler Ulrike
LandOfFree
Nucleic acid sequence encoding lymphoma associated molecule BAL does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid sequence encoding lymphoma associated molecule BAL, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid sequence encoding lymphoma associated molecule BAL will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3401833